Sagimet’s fatty liver disease drug shows promise in trial

(Reuters) – Sagimet Biosciences said on Monday its experimental drug was statistically significant in reducing symptoms of a fatty liver disease in a mid-stage study.

(Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli)